Cargando…

Fluorescein Angiographic Findings of Peripheral Retinal Vasculature after Intravitreal Conbercept versus Ranibizumab for Retinopathy of Prematurity

PURPOSE: To evaluate angiographic findings of peripheral retina vasculature in retinopathy of prematurity (ROP) neonates who received intravitreal conbercept (IVC) or ranibizumab (IVR). METHODS: Fluorescein angiography (FA) findings were retrospectively evaluated for ROP neonates who received IVC or...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jin, Enzhong, Yin, Hong, Gui, Yufei, Chen, Juan, Zhang, Jian, Liang, Jianhong, Li, Xiao-xin, Zhao, Mingwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2019
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955114/ https://www.ncbi.nlm.nih.gov/pubmed/31976086 http://dx.doi.org/10.1155/2019/3935945

Ejemplares similares

A lower dose of intravitreal conbercept effectively treats retinopathy of prematurity
por: Cheng, Yong, et al.
Publicado: (2018)

Different Types of Hyperfluorescence Observed in Post Anti-VEGF Fluorescein Angiographic Patterns in Retinopathy of Prematurity Patients
por: Jin, Enzhong, et al.
Publicado: (2022)

Long-term peripheral retinal vascular behavior in retinopathy of prematurity patients treated with ranibizumab intravitreal injection as monotherapy using fluorescein angiography
por: Al Rasheed, Raghad, et al.
Publicado: (2022)

Evaluation of retinal vascularization in retinopathy of prematurity regressed after intravitreal ranibizumab monotherapy or without treatment based on fluorescein angiography
por: Wu, Lei, et al.
Publicado: (2023)

Intravitreal ranibizumab or conbercept for retinal arterial macroaneurysm: a case series
por: Lin, Zhongjing, et al.
Publicado: (2019)

Intraocular pressure effect of intravitreal conbercept injection for retinopathy of prematurity
por: Gao, Caifeng, et al.
Publicado: (2023)

Intravitreal Ranibizumab for Aggressive Posterior Retinopathy of Prematurity
por: Li, Xiu-Juan, et al.
Publicado: (2016)

Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity
por: Tahija, Sjakon G, et al.
Publicado: (2014)

Efficacy and Safety of Intravitreal Conbercept, Ranibizumab, and Triamcinolone on 23-Gauge Vitrectomy for Patients with Proliferative Diabetic Retinopathy
por: Cui, Jinglin, et al.
Publicado: (2018)

Comparison of efficacy and safety of intravitreal ranibizumab and conbercept before vitrectomy in Chinese proliferative diabetic retinopathy patients: a prospective randomized controlled trial
por: Li, Siying, et al.
Publicado: (2022)

Serum levels of cytokines in infants treated with conbercept for retinopathy of prematurity
por: Cheng, Yong, et al.
Publicado: (2020)

Outcomes and prognostic factors for aggressive posterior retinopathy of prematurity following initial treatment with intravitreal ranibizumab
por: Tong, Qizhe, et al.
Publicado: (2018)

The efficacy of conbercept or ranibizumab intravitreal injection combined with laser therapy for Coats’ disease
por: Zhang, Longli, et al.
Publicado: (2018)

Fluorescein cap: Fluorescein angiographic feature of retinal cavernous hemangioma
por: Kumar, Madhu, et al.
Publicado: (2018)

Combination of Intravitreal Ranibizumab and Laser Photocoagulation for Aggressive Posterior Retinopathy of Prematurity
por: Mota, Ágata, et al.
Publicado: (2012)

Risk of recurrence of retinopathy of prematurity after initial intravitreal ranibizumab therapy
por: Chan, Joyce J. T., et al.
Publicado: (2016)

Intravitreal ranibizumab for retinopathy of prematurity: The ocular and systemic safety profile query
por: Al Kalbani, Khulood, et al.
Publicado: (2023)

Ranibizumab-induced retinal reperfusion and regression of neovascularization in diabetic retinopathy: An angiographic illustration
por: Chandra, Shruti, et al.
Publicado: (2018)

Comparison of clinical outcomes of conbercept versus ranibizumab treatment for retinopathy of prematurity: a multicentral prospective randomised controlled trial
por: Wu, Zhenquan, et al.
Publicado: (2022)

Comparison of the Efficacy and Safety of Intravitreal Conbercept with Intravitreal Ranibizumab for Treatment of Diabetic Macular Edema: A Meta-Analysis
por: Sun, Xiaolei, et al.
Publicado: (2020)

Intravitreal ranibizumab as a primary or a combined treatment for severe retinopathy of prematurity
por: Arámbulo, Odalis, et al.
Publicado: (2015)

Combination therapy of intravitreal ranibizumab and laser photocoagulation for aggressive posterior retinopathy of prematurity
por: Dudani, Ajay I, et al.
Publicado: (2022)

The efficacy and ocular safety following aflibercept, conbercept, ranibizumab, bevacizumab, and laser for retinopathy of prematurity: a systematic review and meta-analysis
por: Chen, Jing, et al.
Publicado: (2023)

Switching to Conbercept in Diabetic Macular Edema After Unsatisfactory Response to Previous Intravitreal Injection of Ranibizumab
por: Xing, Peiyu, et al.
Publicado: (2023)

Featureless retina in diabetic retinopathy: Clinical and fluorescein angiographic profile
por: Shukla, Dhananjay, et al.
Publicado: (2021)

Peripheral Fluorescein Angiographic Findings in Fellow Eyes of Patients with Branch Retinal Vein Occlusion
por: Tsui, Irena, et al.
Publicado: (2013)

Asymmetric Outcomes of Type 1 Retinopathy of Prematurity after Bilateral Intravitreal Ranibizumab Treatment
por: Huang, Qiujing, et al.
Publicado: (2017)

Evaluation of Intravitreal Ranibizumab on the Surgical Outcome for Diabetic Retinopathy With Tractional Retinal Detachment
por: Dong, Feng, et al.
Publicado: (2016)

Network meta-analysis of intravitreal conbercept as an adjuvant to vitrectomy for proliferative diabetic retinopathy
por: Wang, Weiwei, et al.
Publicado: (2023)

The effects of ranibizumab injections on fluorescein angiographic findings and visual acuity recovery in age-related macular degeneration
por: Gungel, Hulya, et al.
Publicado: (2014)

Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease
por: Menke, Marcel N, et al.
Publicado: (2015)

Combination of Intravitreal Injection of Ranibizumab and Photocoagulation for the Treatment of Aggressive Posterior Retinopathy of Prematurity with Vitreous Hemorrhage
por: Xu, Yu, et al.
Publicado: (2016)

Outcomes of early versus deferred laser after intravitreal ranibizumab in aggressive posterior retinopathy of prematurity
por: Gangwe, Anil Babanrao, et al.
Publicado: (2021)

Structural and refractive outcomes of intravitreal ranibizumab followed by laser photocoagulation for type 1 retinopathy of prematurity
por: Hoppe, Charis, et al.
Publicado: (2022)

Response to Comment on: Quantification of anterior chamber reaction after intravitreal injections of conbercept and ranibizumab: a pilot study
por: Liao, Xulong, et al.
Publicado: (2019)

Intravitreous injection of conbercept for bullous retinal detachment: A case report
por: Xiang, Xiao-Li, et al.
Publicado: (2022)

Efficacy of intravitreal injection of conbercept on non-proliferative diabetic retinopathy: a retrospective study
por: Wang, Jing, et al.
Publicado: (2020)

Fluorescein angiographic characteristic in predominantly classic and occult types of neovascular age-related macular degeneration treated with ranibizumab
por: Çavdarlı, Cemal, et al.
Publicado: (2021)

Intravitreal ranibizumab as salvage therapy in an extremely low–birth-weight infant with rush type retinopathy of prematurity
por: Lin, Chun-Ju, et al.
Publicado: (2012)

COMPARISON OF INTRAVITREAL INJECTION OF RANIBIZUMAB VERSUS LASER THERAPY FOR ZONE II TREATMENT-REQUIRING RETINOPATHY OF PREMATURITY
por: Zhang, Guoming, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_r36t4lhu3l8gnrnpjmit65ptio